Join our LinkedIn PATENTSCOPE users Community Group
Feedback
Settings

Settings

Goto Application

1,907 results
Offices all Languages Stemming true Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:A61K39/44

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 191
1.WO/2024/086928BINDING AGENTS TARGETING CD36-EXPRESSING TUMOR CELLS
WO - 02.05.2024
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/CA2023/051415 Applicant KISOJI BIOTECHNOLOGY INC. Inventor YAO, Shugang
The present disclosure generally relates to binding agents that are capable of targeting tumor cells and/or immune cells and their use for treating cancer. The binding agents of the present disclosure comprise one or more antigen binding domains of single domain antibodies which are capable of binding to Cluster of Differentiation 36 (CD36), to Programmed Cell Death protein 1 (PD-1) and/or to Cluster of Differentiation 47 (CD47). The binding agents of the present disclosure are monospecific or multispecific and may be in the form of monomers or multimers.
2.WO/2024/089258ALBUMIN CONJUGATED TO CPG OLIGODEOXYNUCLEOTIDES AS SUPER-BOOSTERS OF IMMUNE RESPONSE
WO - 02.05.2024
Int.Class A61K 39/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
44Antibodies bound to carriers
 Appl.No PCT/EP2023/080098 Applicant AARHUS UNIVERSITET Inventor HOWARD, Kenneth Alan
The present invention relates to albumin-oligodeoxynucleotides conjugates, such as compounds, and compositions comprising a protein conjugate, the conjugate comprising an albumin, one or more proteinaceous parts, and one or more CpG oligonucleotides (ODN). These compounds and compositions finds use as medicaments and/or vaccines, and in methods of treatment. Also disclosed are methods for producing the compound or the composition and kits comprising the necessary tools.
3.WO/2024/076973COMPOSITIONS AND METHODS OF DELIVERING LARGE PROTEINS
WO - 11.04.2024
Int.Class A61K 9/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders
16Agglomerates; Granulates; Microbeadlets
 Appl.No PCT/US2023/075810 Applicant BROWN UNIVERSITY Inventor MATHIOWITZ, Edith
Disclosed are pharmaceutical compositions containing micronized antibodies encapsulated and/or dispersed in polymeric particles for antibody delivery. The judicious identification of (i) a subset of polymers, (ii) polymers with certain average molecular weights, (iii) a subset of antibody loadings, and/or (iv) pre-loading antibody processing, leads to formation of polymeric particles that possess minimal to no initial burst release of micronized antibody at zero time point. The pharmaceutical compositions are formulated for oral, subcutaneous, or percutaneous administration, and are particularly suited for treatment regimens that involve antibody-based therapy.
4.WO/2024/076969ANTI-CD40 ANTIBODIES AND USES THEREOF
WO - 11.04.2024
Int.Class A61K 39/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
44Antibodies bound to carriers
 Appl.No PCT/US2023/075805 Applicant MEMORIAL SLOAN-KETTERING CANCER CENTER Inventor HACKETT, Christopher, S.
The presently disclosed subject matter provides anti-CD40 antibodies or antigen-binding fragments thereof, anti-CD40 Fc fusion proteins (e.g., scFv-Fc fusion proteins binding to CD40), cells comprising the anti-CD antibodies or antigen-binding fragments thereof, cells comprising the anti-CD40 Fc fusion proteins, compositions comprising such cells, and methods of using such cells and compositions for diagnosis and therapies
5.WO/2024/041542A METHOD FOR PROGRAMMATICALLY MANAGING ANTIBODY DISULFIDE BONDS SITE-SPECIFIC MODIFICATION
WO - 29.02.2024
Int.Class A61K 39/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
44Antibodies bound to carriers
 Appl.No PCT/CN2023/114316 Applicant SUZHOU BIOREINNO BIOTECHNOLOGY LIMITED COMPANY Inventor WU, Lili
The present disclosure relates to a method for programmatically managing antibody disulfide bonds site-specific modification, and the modified antibody prepared by the method and the use of the antibody modification.
6.WO/2024/037503ANTIBODY-DRUG CONJUGATES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS
WO - 22.02.2024
Int.Class A61K 47/68
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
 Appl.No PCT/CN2023/112924 Applicant SHANGHAI RUOTUO BIOSCIENCES CO., LTD. Inventor FU, Hong
Provided herein are antibody-drug conjugates, for example, a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease. Additionally, provided herein are functionalized compounds, for example, a compound of Formula (IA), for conjugation with an antibody.
7.WO/2024/036184A HUMAN VH-BASED SCAFFOLD FOR THE PRODUCTION OF SINGLE DOMAIN ANTIBODIES AND THEIR USE
WO - 15.02.2024
Int.Class A61K 39/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
44Antibodies bound to carriers
 Appl.No PCT/US2023/071893 Applicant INTERNATIONAL AIDS VACCINE INITIATIVE Inventor JARDINE, Joseph
Provided herein are a human VH-based scaffold for the production of single domain antibodies and their use.
8.127629MOLÉCULAS DE ANTICUERPO Y CONJUGADOS
AR - 14.02.2024
Int.Class C07K 16/22
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
22against growth factors
 Appl.No P220103086 Applicant ASTRAZENECA AB Inventor FRANK IRVINE COMER
La presente divulgación se refiere a moléculas de anticuerpo que se unen al receptor del factor de crecimiento epidérmico (EGFR) y/o a c-Met y a conjugados que contienen estas moléculas de anticuerpos. Las moléculas de anticuerpo y los conjugados encuentran aplicación, por ejemplo, en el tratamiento del cáncer. Reivindicación 35: Una composición farmacéutica que comprende una molécula de anticuerpo según una cualquiera de las reivindicaciones 1 a 25, o un conjugado según una cualquiera de las reivindicaciones 26 a 34, y un vehículo farmacéuticamente aceptable. Reivindicación 42: Un ácido nucleico, o una pluralidad de ácidos nucleicos, opcionalmente aislados, que codifican una molécula de anticuerpo según una cualquiera de las reivindicaciones 1 a 25. Reivindicación 43: Un vector de expresión, o una pluralidad de vectores de expresión, que comprende un ácido nucleico o una pluralidad de ácidos nucleicos según la reivindicación 42. Reivindicación 44: Una célula hospedadora recombinante que comprende el ácido nucleico o la pluralidad de ácidos nucleicos según la reivindicación 42, o el vector de expresión o la pluralidad de vectores de expresión de la reivindicación 43. Reivindicación 46: Un método según la reivindicación 45, que comprende además aislar y/o purificar la molécula de anticuerpo.
9.WO/2024/028282SITE-SPECIFIC MODIFICATION BY A BBB-SHUTTLE OF ANTIBODY-BASED ENTITIES FOR CROSSING THE BLOOD-BRAIN BARRIER
WO - 08.02.2024
Int.Class A61K 47/68
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
 Appl.No PCT/EP2023/071199 Applicant GATE2BRAIN, S.L. Inventor SÁNCHEZ NAVARRO, Macarena
Conjugates of antibodies and selected peptide shuttles that cross the blood-brain barrier, optionally, also conjugated with an active pharmaceutical ingredient, radiotherapy agent or diagnostic agent, pharmaceutical compositions comprising them, as well as the conjugates for use in medicine and as a diagnostic agent.
10.0002812210TEST SYSTEM BASED ON LIQUID-PHASE BLOCKING INDIRECT “SANDWICH” ELISA VARIANT FOR DETERMINING TITER OF ANTIBODIES AGAINST FOOT-AND-MOUTH DISEASE VIRUS STRAIN “O-N2356/PAKISTAN/2018” OF GENOTYPE O/ME-SA/PANASIA2 ANT-10 IN ANIMAL BLOOD SERUM
RU - 25.01.2024
Int.Class G01N 33/541
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
536with immune complex formed in liquid phase
537with separation of immune complex from unbound antigen or antibody
539involving precipitating reagent
541Double or second antibody
 Appl.No 2023108557 Applicant Inventor Луговская Наталия Николаевна (RU)
FIELD: biotechnology. SUBSTANCE: invention relates to a liquid-phase blocking indirect “sandwich” ELISA test system for determining the titer of antibodies against foot-and-mouth disease virus strain “O No. 2356/Pakistan/2018” of genotype O/ME-SA/PanAsia2ANT-10 in animal blood serum. EFFECT: invention is effective for quantitative determination of antibody titer against foot and mouth disease virus strain “O No. 2356/Pakistan/2018” genotype O/ME-SA/PanAsia2ANT-10 in a wide range of 4.0–10.5 log2 SN50 for subsequent analysis of the immune status of animals against foot and mouth disease. 3 cl, 4 dwg, 7 tbl, 6 ex
# -